Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty

Peripheral nerve blocks catheters of the femoral nerve have long been used for perioperative analgesia in total knee arthroplasty (TKA). These blocks provide effective analgesia and patient satisfaction for surgical pain relief. However, one of the main drawbacks to the femoral nerve block (FNB) is a denser motor block of the quadriceps muscle that can delay aggressive physical therapy and subsequent recovery from surgery. (1) Recently, there has been increasing interest in performing adductor canal blocks (ACB) with the aim of less motor blockade while providing commensurate analgesia compared to the FNB. (1,2) Current investigative reports have provided only preliminary data, and there is potential to change the standard of care for TKA as more data mounts in favor of ACBs. The goal of this study is to verify the analgesic equivalence of the two blocks, compare patient satisfaction, surgeon satisfaction, and physical therapy grading between the two blocks. Potentially, this would change the standard of care for TKA patients at this institution.

Study Overview

• Status: Completed
• Conditions: Arthropathy of Knee
• Intervention / Treatment: Procedure: Adductor Canal Nerve Block; Drug: Femoral Nerve Block

Detailed Description

The specific objectives of this study are to determine the effectiveness of ACB for analgesia compared to FNB as determined by patient reported VAS scores. Determine the effectiveness of ACB for analgesia compared to FNB as determined by opioid usage. Determine the effectiveness of ACB in physical therapy as determined by early ambulation distance. Determine the surgeon satisfaction via survey, and determine if there is any difference in time to discharge between the two blocks.

Participants in the investigational group will received an adductor canal nerve catheter prior to TKA surgery. Participants in the control group will receive a femoral nerve catheter prior to TKA surgery. After surgery, the patient will be seen in the recovery room to bolus the catheters and start continuous infusions of ropivacaine.

The primary endpoints include, Pain Scores (VAS) at immediate post op, 24 hours, and 48 hours, including highest, opioid consumption at 24 hours and 48 hours pain score at any given time post operatively, physical therapist assessment of patient participation 0-100, distance ambulated at 24 to 48 hours, patient satisfaction, surgeon satisfaction, and hours to discharge.

Participants will be recruited, identified, and interviewed by either the study Principal Investigator or one of the co-investigators. The interviewing investigator will confirm eligibility and the absence of any exclusionary criteria. Details of the study (including risks) will be explained to prospective participants to their satisfaction and consent forms will then be signed.

Randomization: Upon enrollment into the study, participants will be randomized 1:1 to either the investigational group (adductor canal nerve catheter) or the control group (femoral nerve catheter). Randomization will be performed using a random number generator Participants in this study will be randomized into two interventional groups. The participant in the "adductor canal nerve catheter" investigational group will receive an adductor canal block catheter placed under direct ultrasound guidance. The participants in the "femoral nerve catheter" control group will receive a femoral nerve clock catheter placed under direct ultrasound guidance with a stimulating needle. Investigational group participants in the adductor canal block arm will receive an adductor canal block catheter placed under direct ultrasound guidance as follows. Patients will be placed supine with their block limb supinated about 20 degrees to facilitate access to the anteromedial thigh. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort.

Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced into the adductor canal. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.

Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-10. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block. The hours to discharge will be calculated.

Control group participants in the femoral nerve block arm will receive a femoral nerve block catheter placed under direct ultrasound guidance with the stimulating needle as follows. Patients will be placed supine with their block limb exposed to facilitate access to the anterior inguinal area. Standard noninvasive monitors will be applied, and oxygen administered via nasal canula. Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping, and draping will be applied to the area. Under ultrasound guidance the needle will be advanced to the femoral nerve. After negative aspiration, a bolus of 20 ml 0.5% Ropivacaine will be injected under direct visualization in 5 mL aliquots ensuring proper placement of the needle tip. The catheter will be advanced in this position at least 2 cm and not more than 5 cm and secured to the skin with tegaderm. Patients will be evaluated immediately post-operatively in the PACU (Post anesthesia care unit) to determine VAS score from 0-10.

Physical therapist and physicians will be asked to complete a short survey after their patient has enrolled in the study. A Waiver of Informed Consent is requested for their participation.

Patients will be given a standard pain regimen while in the hospital. 24 hour opioid consumption will be calculated. Patients will be evaluated 24 and 48 hours post operatively for VAS score, duration of sensory and motor block, and patient satisfaction from 0-10. The catheter will be removed on post operative day 2. Patient will be followed up until nerve block resolved. Physical therapists in the hospital will be surveyed with a standard questionnaire regarding the patients ability to participate in physical therapy sessions on a scale of 0-100. Ambulation distance at 24 and 48 hours will be recorded per their notes. The surgeons performing the procedures will be surveyed in a general sense regarding their impression of patient recovery with this block then the hours will be calculated to the hours to discharge for each patient.

All demographic and clinical variables with continuous measures will be expressed as means and standard deviations; categorical factors will be expressed as proportions. For non-normal data, the medians and inter quartile ranges will be displayed. The distribution of the continuous factors will be examined using the Kolmogorov-Smirnov test. For data that are normally distributed, the one-way ANOVA and Student's t-test will be used to compare groups of data. For data that are not normally distributed, the Kruskal-Wallis and Mann-Whitney tests will be used for comparisons. Chi-square and Fisher's exact tests will be used to analyze categorical data. For all comparisons, a value of p < 0.05 will be considered statistically significant.

Primary Outcome Analysis: Statistical analyses will be performed using SAS for Windows, version 9.2. Student's t-test will be used to compare post-operative pain scores for investigational and control subjects. Linear regression will be also be used to test the relationship between pain scores and regional anesthetic technique, while controlling for relevant clinical and demographic variables. Distance of first ambulation will be analyzed using Cox proportional hazards model. Student's t-test will be used to compare patient and surgeon satisfaction.

Statistical Power and Sample Size Estimates: Sample size (94) was determined using a Cohen's d table assuming a mean pain VAS score of 8 (sd = 3) on a scale of 0-10 for control subjects. A sample of 94 participants (45 patients in the adductor canal block group, and 49 patients in the femoral nerve block group) will have approximately 80% power to detect a reduction in pain score of at least 50%, and approximately 99% to detect an 80% reduction in pain score.

• Study Type: Interventional
• Enrollment (Actual): 94
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35249
      • UAB Department of Anesthesiology and Perioperative Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 100 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient undergoing total knee arthroplasty with regional anesthesia planned for postoperative analgesia.
• Adult, 19 years of age or older
• Patient classified as American Society of Anesthesiology (ASA) class I, II, or III

Exclusion Criteria:

• Any subject not classified as an ASA I, II, or III
• Allergy/intolerance to local anesthetic
• Pre-existing neurologic or anatomic deficit in lower extremity on the side of the surgical site
• Coexisting coagulopathy such as hemophilia or von Willebrand disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Adductor Canal Nerve Block; Participants will be randomized using block randomization.	Procedure: Adductor Canal Nerve Block; Adductor Canal never technique; Other Names: ropivacaine
Active Comparator: Femoral Nerve Block; Participants will be randomized using block randomization.	Drug: Femoral Nerve Block; Traditional technique; Other Names: ropivacaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Distance Ambulated at 24 Hours Post Operatively	Distance ambulated in feet from the end of surgery to 24 hours postoperatively	Baseline up to 24 hours after the Anesthesia Record Stop Time
Mean Distance Ambulated at 48 Hours Post Operatively	Distance ambulated in feet from the end of surgery to 48 hours postoperatively	From the Anesthesia Record Stop Time to 48 hours after the Anesthesia Record Stop Time

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Pain Scores Immediately Preoperatively	Visual Analog Scale (VAS) score immediately preoperatively. The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.	baseline up to time of anesthesia record start time
Mean Opioid Consumption as Measured by Oral Morphine Milligram Equivalents	Preoperatively, opioid consumption will be measured from baseline to the Anesthesia Record Start Time in Oral Morphine Equivalents	from baseline to two hours
Patient Satisfaction at 48 Hours Post Operatively	Patient satisfaction score, on an analog scale from 0-10, with 0 being the lowest satisfaction and 10 being the highest satisfaction.	Baseline up to 48 hrs
Mean Hours to Discharge	Mean hours to discharge, from the time of admittance to the time of discharge	Baseline to discharge (approximately 90 hrs)
Mean Pain Scores in PACU	The Mean Pain Score (VAS) at no more than 4 hours after the Anesthesia Record Stop Time. The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.	Immediately post operatively, not more than 4 hours after pacu admittance
Mean Pain Scores at 24 Hours	Visual Analog Scale (VAS) score at 24 hours from the time of Anesthesia Record Stop Time. The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.	From the Anesthesia Record stop time to 24 hours after Anesthesia Record stop time
Mean Pain Scores 48 Hours Postoperatively	Visual Analog Scale (VAS) score at 48 hours from the time of Anesthesia Record Stop Time. The Visual Analog Scale is a standard numerical pain score reported by the patient, from 0-10, where 0=no pain, and 10=worst pain.	From the Anesthesia Record Stop Time to 48 hours from the Anesthesia Record Stop Time
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents	Mean opioid consumption as measured immediately post operatively from Anesthesia Record Stop Time to 4 hours after Anesthesia Record Stop Time in Oral Morphine Milligram Equivalents	Post operatively through 4 hours
Mean Opioid Consumption as Measured in Oral Morphine Milligram Equivalents	Mean opioid consumption as calculated from the time of Anesthesia Record Stop Time to 24 hours after Anesthesia Record Stop Time in Oral Morphine Equivalents	From immediately post operatively through 24 hours
Mean Opioid Consumption as Measured in Oral Morphine Equivalents	Mean opioid consumption as calculated from Anesthesia Record Stop Time to 48 hours after Anesthesia Record Stop Time in Oral Morphine Milligram Equivalents	From immediately post operatively through 48 hours

Collaborators and Investigators

• Sponsor: University of Alabama at Birmingham
• Investigators: Principal Investigator: Promil Kukreja, MD, University of Alabama at Birmingham

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2014
• Primary Completion (Actual): October 1, 2017
• Study Completion (Actual): January 1, 2019

Study Registration Dates

• First Submitted: April 14, 2017
• First Submitted That Met QC Criteria: April 25, 2017
• First Posted (Actual): April 28, 2017

Study Record Updates

• Last Update Posted (Actual): January 16, 2019
• Last Update Submitted That Met QC Criteria: January 14, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Keywords: Adductor Canal Block; Femoral Canal Block
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Joint Diseases; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Anesthetics, Local; Ropivacaine
• Other Study ID Numbers: F140917004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes